Your browser doesn't support javascript.
loading
HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia.
Lai, Tzung-Huei; Ozer, Hatice Gulcin; Gasparini, Pierluigi; Nigita, Giovanni; Distefano, Rosario; Yu, Lianbo; Ravikrishnan, Janani; Yilmaz, Selen; Gallegos, Juan; Shukla, Sachet; Puduvalli, Vinay; Woyach, Jennifer; Lapalombella, Rosa; Blachly, James; Byrd, John C; Sampath, Deepa.
Afiliação
  • Lai TH; Division of Hematology, The Ohio State University, Columbus, OH.
  • Ozer HG; Department of Biomedical Informatics, The Ohio State University, Columbus, OH.
  • Gasparini P; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH.
  • Nigita G; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH.
  • Distefano R; Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH.
  • Yu L; Center for Biostatistics, The Ohio State University, Columbus, OH.
  • Ravikrishnan J; Division of Hematology, The Ohio State University, Columbus, OH.
  • Yilmaz S; Department of Biomedical Informatics, The Ohio State University, Columbus, OH.
  • Gallegos J; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Shukla S; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Puduvalli V; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Woyach J; Division of Hematology, The Ohio State University, Columbus, OH.
  • Lapalombella R; Division of Hematology, The Ohio State University, Columbus, OH.
  • Blachly J; Division of Hematology, The Ohio State University, Columbus, OH.
  • Byrd JC; Department of Internal Medicine, The University of Cincinnati, Cincinnati, OH.
  • Sampath D; Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood Adv ; 7(12): 2897-2911, 2023 Jun 27.
Article em En | MEDLINE | ID: mdl-36287107
Chronic lymphocytic leukemia (CLL) is a quiescent B-cell malignancy that depends on transcriptional dysregulation for survival. The histone deacetylases are transcriptional regulators whose role within the regulatory chromatin and consequence on the CLL transcriptome is poorly characterized. Here, we profiled and integrated the genome-wide occupancy of HDAC1, BRD4, H3K27Ac, and H3K9Ac signals with chromatin accessibility, Pol2 occupancy, and target expression signatures in CLL cells. We identified that when HDAC1 was recruited within super-enhancers (SEs) marked by acetylated H3K27 and BRD4, it functioned as a transcriptional activator that drove the de novo expression of select genes to facilitate survival and progression in CLL. Targeting HDACs reduced BRD4 and Pol2 engagement to downregulate the transcript and proteins levels of specific oncogenic driver genes in CLL such as BLK, a key mediator of the B-cell receptor pathway, core transcription factors such as PAX5 and IKZF3, and the antiapoptotic gene, BCL2. Concurrently, HDAC1, when recruited in the absence of SEs, repressed target gene expression. HDAC inhibition reversed silencing of a defined set of protein-coding and noncoding RNA genes. We focused on a specific set of microRNA genes and showed that their upregulation was inversely correlated with the expression of CLL-specific survival, transcription factor, and signaling genes. Our findings identify that the transcriptional activator and repressor functions of HDACs cooperate within the same tumor to establish the transcriptional dependencies essential for survival in CLL.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromatina / Leucemia Linfocítica Crônica de Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromatina / Leucemia Linfocítica Crônica de Células B Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2023 Tipo de documento: Article